Covaxin has become the only Covid-19 vaccine in the world to have studied and generated data from trials on kids as young as two years. Results of the trial showed seroconversion at 95-98% in children of all age groups, four weeks after they received their second dose.
Read full Post
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment